{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:18:16Z","timestamp":1787836696833,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T00:00:00Z","timestamp":1280275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s00702-010-0446-z","type":"journal-article","created":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T05:32:27Z","timestamp":1280208747000},"page":"1093-1098","source":"Crossref","is-referenced-by-count":49,"title":["Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson\u2019s disease"],"prefix":"10.1007","volume":"117","author":[{"given":"Gessica","family":"Sala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Brighina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Saracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Fermi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Carrozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pirovano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Ferrarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,28]]},"reference":[{"issue":"2","key":"446_CR1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1369\/jhc.5A6739.2005","volume":"54","author":"M Anlauf","year":"2006","unstructured":"Anlauf M, Sch\u00e4fer MK, Schwark T, von Wurmb-Schwark N, Brand V, Sipos B, Horny HP, Parwaresch R, Hartschuh W, Eiden LE, Kl\u00f6ppel G, Weihe E (2006) Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis. J Histochem Cytochem 54(2):201\u2013213","journal-title":"J Histochem Cytochem"},{"issue":"30","key":"446_CR2","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1523\/JNEUROSCI.0319-07.2007","volume":"27","author":"WM Caudle","year":"2007","unstructured":"Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebrooke RE, Di Monte DA, Emson PC, Miller GW (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27(30):8138\u20138148","journal-title":"J Neurosci"},{"issue":"1","key":"446_CR3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1471-4159.2007.05108.x","volume":"105","author":"MK Chen","year":"2008","unstructured":"Chen MK, Kuwabara H, Zhou Y, Adams RJ, Brasi\u0107 JR, McGlothan JL, Verina T, Burton NC, Alexander M, Kumar A, Wong DF, Guilarte TR (2008) VMAT2 and dopamine neuron loss in a primate model of Parkinson\u2019s disease. J Neurochem 105(1):78\u201390","journal-title":"J Neurochem"},{"issue":"2","key":"446_CR4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.biopsych.2006.03.046","volume":"61","author":"L Christiansen","year":"2007","unstructured":"Christiansen L, Tan Q, Iachina M, Bathum L, Kruse TA, McGue M, Christensen K (2007) Candidate gene polymorphisms in the serotonergic pathway: influence on depression symptomatology in an elderly population. Biol Psychiatry 61(2):223\u2013230","journal-title":"Biol Psychiatry"},{"issue":"9","key":"446_CR5","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1111\/j.1460-9568.2006.05143.x","volume":"24","author":"RE Colebrooke","year":"2006","unstructured":"Colebrooke RE, Humby T, Lynch PJ, McGowan DP, Xia J, Emson PC (2006) Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson\u2019s disease. Eur J Neurosci 24(9):2622\u20132630","journal-title":"Eur J Neurosci"},{"issue":"8","key":"446_CR6","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/archneur.65.8.1074","volume":"65","author":"A DelleDonne","year":"2008","unstructured":"DelleDonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JE, Josephs KA, Frigerio R, Burnett M, Wszolek ZK, Uitti RJ, Ahlskog JE, Dickson DW (2008) Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 65(8):1074\u20131080","journal-title":"Arch Neurol"},{"issue":"4","key":"446_CR7","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.neuroscience.2008.04.051","volume":"154","author":"DE Dluzen","year":"2008","unstructured":"Dluzen DE, Bhatt S, McDermott JL (2008) Differences in reserpine-induced striatal dopamine output and content between female and male mice: implications for sex differences in vesicular monoamine transporter 2 function. Neuroscience 154(4):1488\u20131496","journal-title":"Neuroscience"},{"key":"446_CR8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archneur.56.1.33","volume":"56","author":"DJ Gelb","year":"1999","unstructured":"Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33\u201339","journal-title":"Arch Neurol"},{"issue":"6","key":"446_CR9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WR Gibb","year":"1988","unstructured":"Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 51(6):745\u2013752","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"446_CR10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ana.410440307","volume":"44","author":"S Gilman","year":"1998","unstructured":"Gilman S, Koeppe RA, Adams KM, Junck L, Kluin KJ, Johnson-Greene D, Martorello S, Heumann M, Bandekar R (1998) Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography. Ann Neurol 44(3):326\u2013333","journal-title":"Ann Neurol"},{"issue":"2","key":"446_CR11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/hmg\/ddi445","volume":"15","author":"CE Glatt","year":"2006","unstructured":"Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B (2006) Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet 15(2):299\u2013305","journal-title":"Hum Mol Genet"},{"issue":"2","key":"446_CR12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12035-009-8059-y","volume":"39","author":"TS Guillot","year":"2009","unstructured":"Guillot TS, Miller GW (2009) Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol 39(2):149\u2013170","journal-title":"Mol Neurobiol"},{"key":"446_CR13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0169-328X(95)00278-Z","volume":"36","author":"KA Harrington","year":"1996","unstructured":"Harrington KA, Augood SJ, Kingsbury AE, Foster OJ, Emson PC (1996) Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson\u2019s disease. Brain Res Mol Brain Res 36:157\u2013162","journal-title":"Brain Res Mol Brain Res"},{"key":"446_CR14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427\u2013442","journal-title":"Neurology"},{"issue":"7","key":"446_CR15","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1212\/01.wnl.0000204179.88955.fa","volume":"66","author":"KJ Klos","year":"2006","unstructured":"Klos KJ, Ahlskog JE, Josephs KA, Apaydin H, Parisi JE, Boeve BF, DeLucia MW, Dickson DW (2006) Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 66(7):1100\u20131102","journal-title":"Neurology"},{"issue":"4","key":"446_CR16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4","volume":"47","author":"CS Lee","year":"2000","unstructured":"Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson\u2019s disease. Ann Neurol 47(4):493\u2013503","journal-title":"Ann Neurol"},{"key":"446_CR17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01244941","volume":"93","author":"KP Lesch","year":"1993","unstructured":"Lesch KP, Gross J, Wolozin BL, Murphy DL, Riederer P (1993) Extensive sequence divergence between the human and rat brain vesicular monoamine transporter: possible molecular basis for species differences in the susceptibility to MPP+. J Neural Transm Gen Sect 93:75\u201382","journal-title":"J Neural Transm Gen Sect"},{"issue":"10","key":"446_CR18","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/hmg\/ddi148","volume":"14","author":"Z Lin","year":"2005","unstructured":"Lin Z, Walther D, Yu XY, Li S, Drgon T, Uhl GR (2005) SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum Mol Genet 14(10):1393\u20131404","journal-title":"Hum Mol Genet"},{"issue":"1","key":"446_CR19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1176\/appi.ajp.160.1.47","volume":"160","author":"KY Little","year":"2003","unstructured":"Little KY, Krolewski DM, Zhang L, Cassin BJ (2003) Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry 160(1):47\u201355","journal-title":"Am J Psychiatry"},{"issue":"16","key":"446_CR20","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1128\/MCB.21.16.5321-5331.2001","volume":"21","author":"KA Mooslehner","year":"2001","unstructured":"Mooslehner KA, Chan PM, Xu W, Liu L, Smadja C, Humby T, Allen ND, Wilkinson LS, Emson PC (2001) Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol Cell Biol 21(16):5321\u20135331","journal-title":"Mol Cell Biol"},{"issue":"12","key":"446_CR21","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/sj.npp.1300809","volume":"30","author":"SG Schwab","year":"2005","unstructured":"Schwab SG, Franke PE, Hoefgen B, Guttenthaler V, Lichtermann D, Trixler M, Knapp M, Maier W, Wildenauer DB (2005) Association of DNA polymorphisms in the synaptic vesicular amine transporter gene (SLC18A2) with alcohol and nicotine dependence. Neuropsychopharmacology 30(12):2263\u20132268","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"446_CR22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.euroneuro.2005.02.005","volume":"15","author":"K Schwartz","year":"2005","unstructured":"Schwartz K, Iancu I, Stryjer R, Chelben J, Kotler M, Weizman A, Rehavi M (2005) Reduced platelet vesicular monoamine transporter density in smoking schizophrenia patients. Eur Neuropsychopharmacol 15(5):557\u2013561","journal-title":"Eur Neuropsychopharmacol"},{"issue":"25","key":"446_CR23","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1523\/JNEUROSCI.1495-09.2009","volume":"29","author":"TN Taylor","year":"2009","unstructured":"Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, Iuvone PM, Weinshenker D, Greene JG, Miller GW (2009) Nonmotor symptoms of Parkinson\u2019s disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 29(25):8103\u20138113","journal-title":"J Neurosci"},{"issue":"6","key":"446_CR24","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/mds.20083","volume":"19","author":"JC Zijlmans","year":"2004","unstructured":"Zijlmans JC, Daniel SE, Hughes AJ, R\u00e9v\u00e9sz T, Lees AJ (2004) Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 19(6):630\u2013640","journal-title":"Mov Disord"},{"issue":"2","key":"446_CR25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0006-3223(00)00981-1","volume":"49","author":"JK Zubieta","year":"2001","unstructured":"Zubieta JK, Taylor SF, Huguelet P, Koeppe RA, Kilbourn MR, Frey KA (2001) Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry 49(2):110\u2013116","journal-title":"Biol Psychiatry"},{"issue":"19","key":"446_CR26","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/S0024-3205(01)01301-7","volume":"69","author":"M Zucker","year":"2001","unstructured":"Zucker M, Weizman A, Rehavi M (2001) Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. Life Sci 69(19):2311\u20132317","journal-title":"Life Sci"},{"issue":"3","key":"446_CR27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0165-1781(02)00223-8","volume":"112","author":"M Zucker","year":"2002","unstructured":"Zucker M, Aviv A, Shelef A, Weizman A, Rehavi M (2002) Elevated platelet vesicular monoamine transporter density in untreated patients diagnosed with major depression. Psychiatry Res 112(3):251\u2013256","journal-title":"Psychiatry Res"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-010-0446-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-010-0446-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-010-0446-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:25:19Z","timestamp":1559103919000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-010-0446-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,28]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s00702-010-0446-z","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,28]]}}}